HistoSonics Stock
Developing a non-invasive, autonomous robotic platform capable of destroying tissue at a sub-cellular level
About HistoSonics Stock
HistoSonics, Inc. was created to advance the development of histotripsy, a science discovered and developed by leading scientists at the University of Michigan to provide improved therapies for patients. According to the company, its exclusive license to intellectual property, significant financial support, and strategic partnerships have helped HistoSonics develop Robotically Assisted Sonic Therapy (RAST)™, a novel beam therapy capable of destroying tissue at a sub-cellular level. HistoSonics’ team of specialists and industry leaders is based in Ann Arbor, Michigan.
Funding History
| February 2010 | $14.0M |
|---|---|
| May 2014 | $0 |
| December 2014 | $1.5M |
| September 2015 | $3.5M |
| March 2017 | $8.3M |
| July 2018 | $4.8M |
| April 2019 | $54.0M |
Management
VP of Regulatory & Clinical Affairs
Michael Daniel
CFO
Jon Freeman
VP of Research & Development
Joshua Stopek
VP of Operations
Daniel Bulver
President & CEO
Mike Blue
VP of Marketing
Josh King
Other Companies
EquityZen does not have an affiliation with, formal relationship with, or endorsement from HistoSonics or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
